These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20919830)

  • 1. The potential of immunomodulatory drugs in the treatment of solid tumors.
    Dalgleish A; Galustian C
    Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
    Zeldis JB; Knight R; Hussein M; Chopra R; Muller G
    Ann N Y Acad Sci; 2011 Mar; 1222():76-82. PubMed ID: 21434945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
    Ladizinski B; Shannon EJ; Sanchez MR; Levis WR
    J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide: an immunomodulatory drug.
    Crane E; List A
    Future Oncol; 2005 Oct; 1(5):575-83. PubMed ID: 16556034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in solid tumors.
    Segler A; Tsimberidou AM
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1393-406. PubMed ID: 22584909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide as a novel therapeutic agent: new uses for an old product.
    Teo SK; Stirling DI; Zeldis JB
    Drug Discov Today; 2005 Jan; 10(2):107-14. PubMed ID: 15718159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.